Age Affects Aspirin Response in Patients With Stable CAD

This article originally appeared here.
Age Affects Aspirin Response in Patients With Stable CAD
Age Affects Aspirin Response in Patients With Stable CAD

(HealthDay News) – Age is a significant factor in determining aspirin response in patients with stable coronary artery disease (CAD), according to a study published in the July 15 issue of The American Journal of Cardiology.

Mordehay Vaturi, MD, from Tel-Aviv University in Israel, and colleagues recruited 583 patients with stable CAD who had been treated with aspirin 75–325mg/day for at least one week. Patients were grouped by age: <75 years (438 patients) and patients aged ≥75 years (145). The VerifyNow Aspirin Test was used to determine response, and resistance was defined as ≥500 or 550 aspirin reaction units (ARU).

The researchers found that younger and older patients had similar baseline clinical profiles, including relative doses of aspirin therapy. In patients ≥75 years, the mean VerifyNow Aspirin Test score was significantly higher (450±54 vs. 434±53 ARU. Age remained a significant predictor of the VerifyNow score after adjusting for other variables. When the 500-ARU cut-off was used, aspirin resistance was higher in older patients (19 vs. 11%), but there was no difference when the 550-ARU cut-off was used (7 vs. 5%).

"In conclusion, aspirin response differs significantly by age in patients with stable CAD," the authors write.

Abstract
Full Text (subscription or payment may be required)